Loading...
Market
Will Relay Therapeutics announce further positive data from the RLY-2608 study by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press releases from Relay Therapeutics or reputable news sources
Story
Relay Therapeutics' RLY-2608 Shows Positive Interim Data, Stock Rises 21.2%
Sep 9, 2024, 11:15 AM
Relay Therapeutics announced on Monday positive interim data for its experimental treatment, RLY-2608, which demonstrates clinically meaningful progression-free survival in patients with HR+/HER2- breast cancer. The early-stage study indicates that the combination treatment significantly extended the time patients lived without their disease worsening. Following the announcement, Relay Therapeutics' stock (RLAY) saw a pre-market increase of 21.2%. Dr. Don Bergstrom, President of R&D at Relay Therapeutics, highlighted the significance of these findings.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
